SE0300034D0 - Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals - Google Patents

Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals

Info

Publication number
SE0300034D0
SE0300034D0 SE0300034A SE0300034A SE0300034D0 SE 0300034 D0 SE0300034 D0 SE 0300034D0 SE 0300034 A SE0300034 A SE 0300034A SE 0300034 A SE0300034 A SE 0300034A SE 0300034 D0 SE0300034 D0 SE 0300034D0
Authority
SE
Sweden
Prior art keywords
pharmaceuticals
strains
anticancer
parapox ovis
ovis virus
Prior art date
Application number
SE0300034A
Other languages
English (en)
Other versions
SE0300034L (sv
Inventor
Olaf Weber
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SE0300034D0 publication Critical patent/SE0300034D0/sv
Publication of SE0300034L publication Critical patent/SE0300034L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0300034A 2000-07-11 2003-01-10 Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer SE0300034L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
PCT/EP2001/007991 WO2002004002A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs

Publications (2)

Publication Number Publication Date
SE0300034D0 true SE0300034D0 (sv) 2003-01-10
SE0300034L SE0300034L (sv) 2003-03-03

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300034A SE0300034L (sv) 2000-07-11 2003-01-10 Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer

Country Status (36)

Country Link
US (1) US6685950B2 (sv)
EP (1) EP1303286B1 (sv)
JP (1) JP5037775B2 (sv)
CN (1) CN1455674B (sv)
AR (1) AR029954A1 (sv)
AT (1) ATE324115T1 (sv)
AU (2) AU7063101A (sv)
BG (1) BG107448A (sv)
CA (1) CA2415397C (sv)
CY (1) CY1105408T1 (sv)
CZ (1) CZ200371A3 (sv)
DE (1) DE50109630D1 (sv)
DK (2) DK1303286T3 (sv)
EE (1) EE200300018A (sv)
ES (1) ES2262663T3 (sv)
FI (1) FI20030037A (sv)
GB (1) GB2381454B8 (sv)
HK (1) HK1054329B (sv)
HR (1) HRP20030096A2 (sv)
HU (1) HUP0400479A3 (sv)
IL (1) IL153643A0 (sv)
LT (1) LT5079B (sv)
LU (1) LU90997B1 (sv)
LV (1) LV12990B (sv)
MA (1) MA26927A1 (sv)
MX (1) MXPA03000279A (sv)
NO (1) NO20030082D0 (sv)
NZ (1) NZ523534A (sv)
PL (1) PL366397A1 (sv)
PT (1) PT1303286E (sv)
RU (1) RU2003104525A (sv)
SE (1) SE0300034L (sv)
SI (1) SI21122A (sv)
SK (1) SK362003A3 (sv)
UY (1) UY26832A1 (sv)
WO (1) WO2002004002A2 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EP1598425A1 (en) * 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
AU2002353031A1 (en) 2001-12-07 2003-06-23 Bayer Corporation Use of parapox b2l protein to treat cancer and modify immune responses
ES2288609T5 (es) * 2002-04-19 2017-11-13 Bavarian Nordic A/S Virus vaccinia ankara modificado para la vacunación de neonatos
PL215169B1 (pl) * 2002-09-05 2013-10-31 Bavarian Nordic As Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki
CN103800382A (zh) * 2004-07-13 2014-05-21 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
EP1951274B1 (en) * 2005-11-24 2009-12-02 AiCuris GmbH & Co. KG Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
DK2513311T4 (da) * 2009-12-18 2021-06-14 Bavarian Nordic As Produktion af ifn-lambda ved hjælp af traditionelle dendritceller og anvendelser deraf
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) * 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
WO1997032029A1 (de) * 1996-02-28 1997-09-04 Bayer Aktiengesellschaft Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
CA2250041A1 (en) * 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
PT885013E (pt) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr Utilizacao de indutores de para-imunidade multipotentes baseados em poxvirus ou parapoxvirus atenuados e nao imunogenicos para a fabricacao de medicamentos
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
NZ511119A (en) * 1998-11-02 2004-04-30 Ludwig Inst Cancer Res Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2

Also Published As

Publication number Publication date
RU2003104525A (ru) 2004-06-27
AU7063101A (en) 2002-01-21
WO2002004002A2 (de) 2002-01-17
IL153643A0 (en) 2003-07-06
DK200300015A (da) 2003-03-07
US6685950B2 (en) 2004-02-03
GB2381454A (en) 2003-05-07
NO20030082L (no) 2003-01-08
GB2381454A8 (en) 2007-10-23
CY1105408T1 (el) 2010-04-28
SI21122A (sl) 2003-08-31
MXPA03000279A (es) 2004-04-05
CZ200371A3 (cs) 2003-04-16
BG107448A (bg) 2003-11-28
JP2004517807A (ja) 2004-06-17
LV12990B (en) 2003-08-20
EP1303286B1 (de) 2006-04-26
GB2381454B8 (en) 2007-10-23
SE0300034L (sv) 2003-03-03
NZ523534A (en) 2005-02-25
LT2003009A (en) 2003-08-25
PT1303286E (pt) 2006-08-31
WO2002004002A3 (de) 2002-10-31
US20030021769A1 (en) 2003-01-30
GB2381454B (en) 2004-11-24
NO20030082D0 (no) 2003-01-08
AR029954A1 (es) 2003-07-23
GB0302630D0 (en) 2003-03-12
HUP0400479A3 (en) 2006-02-28
HRP20030096A2 (en) 2005-02-28
DE50109630D1 (de) 2006-06-01
CA2415397C (en) 2011-04-26
CN1455674A (zh) 2003-11-12
LT5079B (lt) 2003-12-29
FI20030037A (sv) 2003-03-10
ES2262663T3 (es) 2006-12-01
CA2415397A1 (en) 2002-01-17
AU2001270631B2 (en) 2005-07-07
JP5037775B2 (ja) 2012-10-03
SK362003A3 (en) 2003-07-01
HUP0400479A2 (hu) 2004-06-28
EE200300018A (et) 2004-10-15
EP1303286A2 (de) 2003-04-23
ATE324115T1 (de) 2006-05-15
PL366397A1 (en) 2005-01-24
HK1054329A1 (en) 2003-11-28
DK1303286T3 (da) 2006-08-28
CN1455674B (zh) 2019-03-29
UY26832A1 (es) 2002-01-31
HK1054329B (zh) 2005-10-07
MA26927A1 (fr) 2004-12-20
LU90997B1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
MY159370A (en) Semi-soft-class immunostimulatory oligonucleotides
MY144616A (en) Substituted dihydroquinazolines
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
WO2005063734A3 (de) Substituierte thiophene
WO2004071426A3 (en) Compounds for the treatment of viral infection
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
JP2006507295A5 (sv)
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
LT2003008A (en) Parapox ovis virus for use against organ fibrosis
BR0112407A (pt) Uso de cepas de parapoxvìrus ovis para produzir medicamentos antivirais e medicamentos contra câncer
WO2003000274A3 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
ATE489966T1 (de) Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids
WO2003032905A3 (en) Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity
WO2018056528A3 (ko) 인플루엔자 b 백신
WO2005010163A3 (en) Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
WO2005002504A3 (en) Protection against vertical transmission of pathogenic infections
UY28580A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
UA4626U (uk) Бівалентна інактивована концентрат-вакцина проти інфекційного ринотрахеїту та вірусної діареї великої рогатої худоби

Legal Events

Date Code Title Description
NAV Patent application has lapsed